#United States #Franklin Lakes #portal hypertension #BD Technologies #Liverty TIPS

BD's Next-Generation TIPS Technology

BD (Becton, Dickinson and Company), a global leader in medical technology, has taken a significant step forward in the treatment of portal hypertension with the announcement of its newest innovation, the Liverty™ TIPS Stent Graft. This innovative product, which has received CE marking, aims to provide new hope for patients suffering from advanced liver disease in the European Union.

Addressing a Global Health Challenge

According to recent studies from the Global Burden of Disease project, approximately 58 million people worldwide suffer from liver cirrhosis, a serious condition that often leads to portal hypertension. This complication can cause dire health issues, including life-threatening variceal bleeding and fluid accumulation in the abdomen or chest. TIPS (transjugular intrahepatic portosystemic shunt) procedures are crucial in relieving symptoms caused by elevated portal pressure by improving blood flow and reducing pressure in the portal vein.

Introducing the Liverty™ TIPS Stent Graft

The Liverty™ TIPS Stent Graft has been specifically designed to enhance patient care with its adjustable inner diameter, ranging from 6 to 10 mm. It also offers the widest variety of lengths in over-the-balloon TIPS stents, making it adaptable to individual patient needs. Its key features include:

• - A flexible, self-expanding nitinol frame
• - A two-layer ePTFE coating with carbon impregnation on the inside
• - It comes preloaded on a triaxial delivery system, ensuring precise placement, control, and ease of use.

Rima Alameddine, global president of BD's Peripheral Intervention division, emphasized the importance of accessible, effective, and customizable treatment options for patients dealing with complications of portal hypertension. This new CE-marked device provides an innovative solution that allows physicians to tailor therapies for their patients, potentially improving long-term outcomes.

Upcoming Presentation of Clinical Data

Furthermore, the clinical data from the ARCH study, a pivotal global, prospective, multi-center, single-arm clinical trial, will be presented for the first time at the annual meeting of the Society of Interventional Radiology (SIR) on April 12, 2026. These data will assess the safety and effectiveness of the Liverty™ TIPS Stent Graft in treating complications due to portal hypertension.

Prof. Ziv Haskal, the global principal investigator of this study, noted its significance: “The Liverty™ TIPS Stent Graft represents a considerable advance in the treatment of patients with severe complications resulting from portal hypertension. Its adjustable diameter and delivery design allow for improved adaptability to each patient’s individual physiology—an essential factor for the safe and effective placement of a TIPS.”

Conclusion

In the United States, the Liverty™ TIPS Stent Graft is currently an investigational product, and its use is restricted to research purposes according to U.S. law. BD remains committed to advancing healthcare globally through innovative technologies, solutions, and engagement with healthcare stakeholders to enhance clinical operations and patient care. For more information, visit bd.com or connect with BD on social media.

By introducing this cutting-edge stent graft, BD continues to lead the way in interventions for complex liver diseases and highlights the ongoing need for advancements in treatment options for portal hypertension.